Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to ...
Bolstered by its portfolio of “revolutionary” therapies, AbbVie remains the top pharma company in the immunology space, ...
Following an investigation regarding antitrust practices against Pharmacosmos’ Monofer, CSL Vifor has proposed a sweeping ...
All signs point to 2024 surpassing 2023 as a landmark year for cell and gene therapy,” David Barrett, CEO of the American ...
Drugmakers, including the genetic testing company 23andMe, are using novel approaches to stimulate NK cells’ intrinsic ...
A one-time treatment for Parkinson’s disease could be a ‘market changer,’ experts told BioSpace, adding that cell therapies ...
While Madrigal Pharmaceuticals secured the first FDA drug approval for metabolic dysfunction–associated steatohepatitis, ...
The FDA will close out April with five target action dates around indications that include pediatric seizures and a ...
Boehringer Ingelheim has struck a deal with Ochre Bio, announcing Monday an agreement potentially worth more than $1 billion ...
Teva Pharmaceuticals and Alvotech got the FDA’s greenlight for their biosimilar to Johnson & Johnson’s blockbuster Stelara, ...
French healthcare and pharma company Sanofi will terminate an undisclosed number of positions in its U.S. vaccines commercial ...
The clinical-stage biotech emerged from stealth on Thursday with several oral and injectable candidates, including a GLP-1 ...